Sep 30, 2019
Synthetic Lethality-based Drugs and Targets Market, 2030
May 15, 2019
Sierra to Present SRA737 Preliminary Clinical Data and Potential Next Steps at ASCO
Jan 23, 2019
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit
Nov 29, 2018
Sierra Oncology Reports Preclinical Efficacy for Immunotherapy Combination with its Chk1 inhibitor SRA737
Aug 07, 2018
Sierra Oncology to Present at the Wedbush PacGrow Healthcare Conference in New York
May 10, 2018
Sierra Oncology Reports First Quarter Results
Apr 17, 2018
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting
Mar 19, 2018
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York
Mar 14, 2018
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting
Feb 27, 2018
Sierra Oncology Reports 2017 Year End Results
Feb 27, 2018
Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study
Feb 21, 2018
Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting
Feb 06, 2018
Sierra Oncology to host Program Update in New York on February 27th
Jan 29, 2018
Sierra Oncology to Present at the DNA Damage Response Therapeutics Summit
Nov 08, 2017
Sierra Oncology Reports Third Quarter Results
Nov 07, 2017
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference
Oct 30, 2017
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy
Oct 25, 2017
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors
Oct 16, 2017
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017
Oct 11, 2017
Sierra Oncology to Present at the 2017 BIO Investor Forum